Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Choline Theophyllinate→

Choline Theophyllinate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
4499-40-5
Molecular formula
C12H21N5O3
Molecular weight
283.33 g/mol
Drug class
Theophylline salt complexmethylxanthine bronchodilator
Mechanism of action
Dissociates to release theophylline, which produces bronchodilation mainly through non-selective phosphodiesterase inhibition and adenosine-receptor antagonism, increasing intracellular cyclic AMP in bronchial smooth muscle. Choline is a counter-ion and does not confer a separate therapeutic mechanism.
Indications / reported uses
  • Historically used for bronchodilation in asthma and reversible obstructive airway disease in countries where products remain authorised; current use is limited by the narrow therapeutic index of theophylline and availability of safer alternatives

Sources: NLM MeSH — Theophylline/choline theophyllinate · PubMed — Choline theophyllinate · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Choline Theophyllinate Environmental Risk Assessment (ERA) (the Choline Theophyllinate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.